Clinical Scorecard: Local Autoantibody Production in Subarachnoid Neurocysticercosis Driven by Molecular Mimicry

At a Glance

Key Highlights

• SANCC is characterized by chronic inflammation due to aberrant cyst growth in subarachnoid spaces causing relapsing/remitting symptoms.
• Significant IgG autoantibody reactivity in CSF against human ANXA8 and BAP18 proteins and their T. solium homologues was identified.
• Molecular mimicry between Taenia-derived annexin and metabolic enzymes and human proteins likely drives local autoantibody production contributing to SANCC pathology.

Guideline-Based Recommendations

Diagnosis

• Consider screening CSF for autoantibodies against human brain-associated antigens such as ANXA8 and BAP18 in SANCC patients.
• Use proteome array and Luciferase ImmunoPrecipitation System (LIPS) assays for detecting specific autoantibodies in CSF and serum.

Management

• Recognize the role of autoantibodies in SANCC pathogenesis to inform potential immunomodulatory therapeutic strategies.
• Continue antiparasitic and anti-inflammatory treatments while considering the contribution of autoimmunity.

Monitoring & Follow-up

• Monitor CSF autoantibody levels as potential biomarkers for disease activity and treatment response in SANCC.

Risks

• Autoantibody-mediated inflammation may exacerbate CNS damage and contribute to morbidity and mortality in SANCC.

Patient & Prescribing Data

Patients diagnosed with subarachnoid neurocysticercosis

Autoantibody presence suggests a possible benefit from therapies targeting immune-mediated inflammation in addition to antiparasitic agents.

Clinical Best Practices

• Obtain CSF and serum samples for comprehensive autoantibody screening in SANCC patients.
• Employ molecular mimicry analysis to identify potential cross-reactive antigens driving autoimmunity.
• Integrate findings of autoantibody presence into multidisciplinary management plans including infectious disease and neurology specialists.

References

• NIH Natural History of Treated Neurocysticercosis and Long-Term Outcomes
• NIH Blood Bank Control Samples
• Healthy Control CSF Collection Protocol